Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,344.00
(
-1.59%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.44
(
3.84%
)
Bitcoin
70,464.00
(
0.81%
)
News Focus
News Focus
Post# of 257264
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: dewophile post# 176693

Friday, 04/11/2014 7:09:20 PM

Friday, April 11, 2014 7:09:20 PM

Post# of 257264
>> MRK: for example they ran their 8 week arm in GT1a patients, not the presumably easier to treat 1b subtype.

MRK's C-WORTHy trial includes not only 8-week arm for GT1a with RBV but also two arms for GT1b with or without RBV. They just haven't reported results from those two arms yet probably because they added these arms later on.

http://clinicaltrials.gov/ct2/show/NCT01717326?term=MK-5172+%2B+MK-8742+phase+3&rank=6&submit_fld_opt=
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today